Subscribe to RSS
DOI: 10.1055/s-0040-1704153
CLINICAL VALIDATION OF BLI ADENOMAS SERRATED INTERNATIONAL CLASSIFICATION (BASIC) FOR RESECT AND DISCARD STRATEGY FOR DIMINUTIVE COLORECTAL POLYPS (BIRD STUDY)
Publication History
Publication Date:
23 April 2020 (online)
Aims Blue Light Imaging (BLI) Adenomas Serrated International Classification (BASIC) has been shown to accurately predict histology of ≤10 mm colorectal polyps in an artificial setting with BLI. Study aim: to validate BASIC in a clinical setting by using as reference standard the thresholds recommended by the American Society for Gastrointestinal Endoscopy for resect and discard (R&D) strategy.
Methods Consecutive outpatients referred for screening colonoscopy were included. Six endoscopists trained in BASIC participated in the study. All detected diminutive polyps were real-time BLI-characterized as adenoma or non-adenoma according to BASIC. All polyps were removed and sent for histopathology evaluation. Two thresholds were set:
I) a ≥90% accuracy in surveillance intervals prediction based on high-confidence predictions
of ≤ 5mm polyps (and pathology for the others);
II) a ≥90% negative predictive value for ≤ 5mm rectosigmoid polyps characterized with high-confidence.
The post-polypectomy surveillance intervals were based on both US Multisociety Task Force (USMSTF) and European Society of Gastrointestinal Endoscopy (ESGE) recommendations.
Results 333 patients (mean age±SD: 62.7 ± 8.1 years; M/F: 176/157) were included. BASIC accuracy in 748 ≤ 5 mm polyps was 89% (95%CI: 85.9-90.6). The BLI-directed post-polypectomy surveillance interval was correctly predicted in 90% (95%CI: 86-93%) and in 96% (95%CI: 93-97%) of patients, according to USMSTF and ESGE recommendations, respectively. Out of 748 ≤ 5 mm polyps, 334 were located in the rectosigmoid and 302 (90%) assessed with high-confidence; the negative predictive value for adenomatous histology was 91% (95CI %: 85-95%).
Conclusions The adoption of BASIC classification in clinical practice succeeded to match both of the reference thresholds for R&D strategy. (ClinicalTrialRegistrationNumber: NCT03746171)